共 247 条
[1]
Chan HC(2017)Emerging biologics in inflammatory bowel disease J Gastroenterol 52 141-150
[2]
Ng SC(2018)Area of residence and socioeconomic factors reduce access to biologics for rheumatoid arthritis patients in Romania Biomed Res Int 2018 7458361-731
[3]
Codreanu C(2018)Stopping biologics in IBD—what is the evidence? Inflamm Bowel Dis 24 725-1315
[4]
Popescu CC(2019)Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn's disease in Asia J Gastroenterol Hepatol 34 1296-43
[5]
Mogosan C(2018)PCN32—the effectiveness and safety of switching from orginal filgrastim to biosimilar filgrastim in primary prophylaxis of chemotherapy induced febrile neutropenia: a retrospective cohort study Value Health 21 S20-973
[6]
Louis E(2013)Switching from originator to biosimilar human growth hormone using dialogue teamwork: single-center experience from Sweden Biol Ther 3 35-77
[7]
Ooi CJ(2017)Effectiveness of switch to erythropoiesis-stimulating agent (ESA) biosimilars versus maintenance of ESA originators in the real-life setting: matched-control study in hemodialysis patients Clin Drug Investig 37 965-1568
[8]
Hilmi I(2017)Bristol cup posters Brit J Dermatol 2017 25-1091
[9]
Banerjee R(2006)The epidemiology of inflammatory bowel disease in Canada: a population-based study Am J Gastroenterol 101 1559-1471
[10]
Al Rabayah AA(2019)Trends in the prevalence and incidence of psoriasis and psoriatic arthritis in Ontario, Canada: a population-based study Arthritis Care Res (Hoboken) 71 1084-e1131